NASDAQ: LABTLakewood Amedex Biotherapeutics Inc Stock
$2.05-0.27 (-11.64%)
Updated Sep 10, 2026
LABT Price
$2.05
Fair Value Price
-$1.02
Market Cap
$4.86M
52 Week Low
$1.66
52 Week High
$98.20
P/E
-0.18x
P/B
1.12x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.35M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.15
Operating Cash Flow
N/A
Beta
-1.83
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LABT Overview
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LABT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LABT
Ranked#400 of 460
Ranked#400 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.17 | A | |
| $6.68 | A | |
| $114.92 | A |
Be the first to know about important LABT news, forecast changes, insider trades & much more!
LABT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LABT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LABT ($2.05) is overvalued by 300.63% relative to our estimate of its Fair Value price of -$1.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LABT ($2.05) is not significantly undervalued (300.63%) relative to our estimate of its Fair Value price of -$1.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LABT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LABT due diligence checks available for Premium users.
Valuation
LABT fair value
Fair Value of LABT stock based on Discounted Cash Flow (DCF)
Price
$2.05
Fair Value
-$1.02
Undervalued by
300.63%
LABT ($2.05) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LABT ($2.05) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LABT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LABT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.18x
Industry
9.27x
Market
40.17x
LABT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.12x
Industry
5.33x
LABT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LABT's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.8M
Profit Margin
0%
Assets to liabilities
Assets
$5.0M
Liabilities
$628.9k
Debt to equity
0.15
LABT's short-term assets ($4.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LABT's short-term assets ($4.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LABT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.1M
Investing
$0.0
Financing
$6.7M
LABT vs Biotech Stocks
Lakewood Amedex Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.